Intersection of Cardiology and Oncology Clinical Practices
نویسندگان
چکیده
INTRODUCTION Globally, cancer is diagnosed in approximately 13 million people each year. Approximately 1.6 million cancer patients are seen by cancer clinics across the United States (US) at this time. Over the next two decades, cancer incidence is estimated to increase by approximately 45% to 2.3 million (1). In the US, the 5-year relative survival rate of patients diagnosed with cancer in 1975–1977 was 50%, improving to 68% in the period 1999–2005. Novel targeted chemotherapeutic agents and improved diagnostic techniques are responsible for this increased survival. However, with the improvement in life expectancy, the adverse effects of chemotherapeutic agents, especially cardiotoxicity, is an emerging health problem. Cardiovascular toxicity on its own has a detrimental effect on both the quantity and quality of life independent of the oncological prognosis. Currently, more than two million women with breast cancer are at risk of anthracycline cardiotoxicity in the US (2). Human epidermal growth factor receptor II (HER2) positive disease comprises approximately 25% of all breast cancer patients and is associated with more aggressive disease activity and worse prognosis. Trastuzumab, a humanized monoclonal antibody used for patients with HER2 positive breast cancer in conjugation with chemotherapy, can provide longer survival and 20% reduction in risk of death (3). Cardiotoxicity becomes an important health issue because up to 27% of women with breast cancer receiving anthracyclines, cyclophosphamide, and trastuzumab showed cardiac dysfunction (3). Breast cancer mortality is reduced by approximately one-third, but the risk of heart toxicity is five times more likely for women receiving trastuzumab than women receiving standard therapy alone (4). Patients showing signs of cardiotoxicity often require a dose reduction, a change in the schedule dosing or even cessation of treatment with attendant consequences. Many patients with an asymptomatic decrease in left ventricular ejection fraction (LVEF) are receiving neither the American College of Cardiology/American Heart Association Class I-indicated treatments nor cardiovascular specialty consultation (5). Concern for cardiotoxicity is not restricted to breast cancer survivors. Based on National Cancer Institute (NCI) data, the number of new renal cancer patients in 2013 is expected to be 65,000. In Europe, the incidence of renal cell carcinoma (RCC) has doubled in the last three decades (6). Improved treatment strategies have increased the 5-year survival of patients with RCC from 50% in 1975–1977 to 72% in 2002–2008. Within the last decade, the US Food and Drug Administration (FDA) has approved six drugs for the treatment of RCC including multitargeted tyrosine kinase inhibitors (TKIs); antibodies to vascular endothelial growth factor (VEGF); and mammalian target of rapamycin (mTOR) inhibitors. Sunitinib, a novel multitargeted TKI, has proven efficacy in advanced metastatic RCC demonstrating an increased median progression free survival of 8.3 months in these patients (7). In a study by Hall et al. (8), five of the approved targeted therapy drugs (sorafenib, pazopanib, bevacizumab, everolimus, and temsirolimus) have cardiotoxic side effects. In this 159patient study, 73% of patients experienced some form of cardiotoxicity ranging from hypertension to severe heart failure (8). In a cohort of patients with renal and nonrenal carcinoma, sunitinib was found to be associated with a 3.3-fold higher risk of heart failure (9). Other targeted agents such as imatinib mesylate, Dasatinib, Nilotinib, and Sorafenib are prescribed for treatment of various hematological malignancies, hepatocellular carcinoma (HCC), gastrointestinal stromal tumor (GIST), and myeloproliferative/myelodysplastic diseases and have been shown to be strongly associated to cardiotoxicity (10–13). Imatinib has been shown to be associated with decline in LVEF, especially in patients with other comorbidities including coronary artery disease, diabetes, and hypertension (10).
منابع مشابه
An overview of clinical PET/CT
This article is intended to provide an overview of various aspects of clinical PET/CT. These include discussions of: (i) Important areas of clinical application; (ii) Opportunities in clinical research; (iii) Scanner and operating-mode considerations (e.g. BGO vs. LSO, LYSO or GSO scanners, 2D vs. 3D imaging). (iv) Study-specific considerations (e.g. patient preparation and positioning is...
متن کاملComputed tomography based attenuation correction in PET/CT: Principles, instrumentation, protocols, artifacts and future trends
The advent of dual-modality PET/CT imaging has revolutionized the practice of clinical oncology, cardiology and neurology by improving lesions localization and the possibility of accurate quantitative analysis. In addition, the use of CT images for CT-based attenuation correction (CTAC) allows to decrease the overall scanning time and to create a noise-free attenuat...
متن کاملGlobal Problem of Hospital Detention Practices
Although an official definition by the World Health Organization (WHO) or any other authority is currently lacking, hospital detention practices (HDP) can be described as: “refusing release of either living patients after medical discharge is clinically indicated or refusing release of bodies of deceased patients if families are unable to pay their hospital bills.” Reports of HDP are very scarc...
متن کاملDoes the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis?
Several lines of evidence suggest that hypertension and angiogenesis may be related phenomena but a functional link remains elusive. Here, we propose that the renin-angiotensin system (RAS), in addition to its central role in arterial hypertension, also regulates blood vessel formation during normal development and cancer. This mechanistic hypothesis is based on reports of biochemical, genetic,...
متن کاملCONUT: A Useful Alarm of Malnutrition in the Centralized Laboratory of a Spanish Hospital
Background: Hospital malnutrition, usually secondary to various diseases and their treatments, is an important problem in our clinical practice. For its proper assessment, it is crucial to use a nutritional alert system, such as the CONUT (COntrol NUTrition) program; this tool uses 3 analytical parameters: serum albumin, total cholesterol, and total lymphocyte count. <str...
متن کاملEuropean Society of Cardiology And European Society for Medical Oncology.
Key European Society of Cardiology sessions focused on reducing inflammation, lowering cardiovascular risk and cholesterol, and controlling hypertension, while significant clinical trials of medications for ovarian, lung, gastric, and head-and-neck cancers were presented at the European Society for Medical Oncology congress.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 4 شماره
صفحات -
تاریخ انتشار 2014